The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Pfizer Files Xalkori for ROS1-Positive Lung Cancer in Japan
September 1, 2016
- Harvoni Outstrips Plavix to Top FY2015 Japan Sales Ranking: Jiho Tally
September 1, 2016
- Kyowa Kirin Completes Construction of API Manufacturing Facility for Biopharmaceuticals
September 1, 2016
- Lonsurf Now Available in UK with Health Coverage: Taiho
August 31, 2016
- Data Support Lixiana’s Efficacy in AF Patients Undergoing Cardioversion
August 31, 2016
- Mitsubishi Tanabe’s ALS Drug Gets PDUFA Date of June 16, 2017
August 31, 2016
- Sumitomo Dainippon to Shed Jobs for Leaner Japan Operations
August 31, 2016
- Lilly to Withdraw Taltz from Wholesaler Inventory; Distributor Execs Irked by MHLW’s Price Handling
August 31, 2016
- Santen, Kerui Set Up Ophthalmic JV in China
August 31, 2016
- Oropharyngeal Candidiasis Drug Hits Primary Endpoint in PIII: Sosei
August 30, 2016
- Seikagaku, Ferring Finalize Licensing Deal for Lumbar Disc Herniation Drug
August 30, 2016
- Nichi-Iko Completes Tender Offer for Sagent
August 30, 2016
- Shionogi’s Sakigake-Designated Flu Med Shows Efficacy in Japan PII
August 30, 2016
- Hisamitsu’s NSAIDs Patch Disappoints in Japan PII/III
August 30, 2016
- Mylan, Pfizer Recalling 2 Generic Products in Japan
August 29, 2016
- Vimpat Filed for Monotherapy Approval in Japan: Daiichi Sankyo, UCB
August 29, 2016
- Sizzling DOAC Market - 4: Companies Aim to Differentiate Their Products through Quality of Information
August 29, 2016
- CSL Behring Seeks Approval of Human Prothrombin Complex
August 26, 2016
- Actemra Filed for Weekly Dosage for Inadequately Controlled RA
August 26, 2016
- Mitsubishi Tanabe Transitions from “Open Innovation” to “Open Shared” System: President
August 26, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…